X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PIRAMAL ENTERPRISES VENUS REMEDIES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -821.4 36.5 - View Chart
P/BV x 0.2 3.6 6.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
PIRAMAL ENTERPRISES
Mar-16
VENUS REMEDIES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2181,065 20.5%   
Low Rs82805 10.2%   
Sales per share (Unadj.) Rs365.6383.0 95.5%  
Earnings per share (Unadj.) Rs1.555.1 2.7%  
Cash flow per share (Unadj.) Rs37.974.1 51.2%  
Dividends per share (Unadj.) Rs017.50 0.0%  
Dividend yield (eoy) %01.9 0.0%  
Book value per share (Unadj.) Rs382.5719.9 53.1%  
Shares outstanding (eoy) m11.44172.56 6.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.4 16.8%   
Avg P/E ratio x101.017.0 594.9%  
P/CF ratio (eoy) x4.012.6 31.3%  
Price / Book Value ratio x0.41.3 30.2%  
Dividend payout %031.8 0.0%   
Avg Mkt Cap Rs m1,717161,344 1.1%   
No. of employees `0001.03.8 27.0%   
Total wages/salary Rs m32416,898 1.9%   
Avg. sales/employee Rs Th4,100.717,472.6 23.5%   
Avg. wages/employee Rs Th318.04,466.9 7.1%   
Avg. net profit/employee Rs Th16.72,512.8 0.7%   
INCOME DATA
Net Sales Rs m4,18366,099 6.3%  
Other income Rs m202,425 0.8%   
Total revenues Rs m4,20368,524 6.1%   
Gross profit Rs m81218,723 4.3%  
Depreciation Rs m4173,274 12.7%   
Interest Rs m3809,388 4.0%   
Profit before tax Rs m358,485 0.4%   
Minority Interest Rs m03 0.0%   
Prior Period Items Rs m01,593 0.0%   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m181,032 1.8%   
Profit after tax Rs m179,506 0.2%  
Gross profit margin %19.428.3 68.5%  
Effective tax rate %51.612.2 424.0%   
Net profit margin %0.414.4 2.8%  
BALANCE SHEET DATA
Current assets Rs m2,77147,488 5.8%   
Current liabilities Rs m1,931104,362 1.9%   
Net working cap to sales %20.1-86.0 -23.3%  
Current ratio x1.40.5 315.3%  
Inventory Days Days12541 307.9%  
Debtors Days Days5451 105.1%  
Net fixed assets Rs m5,32826,532 20.1%   
Share capital Rs m114345 33.1%   
"Free" reserves Rs m4,177114,024 3.7%   
Net worth Rs m4,376124,221 3.5%   
Long term debt Rs m1,91175,812 2.5%   
Total assets Rs m8,428308,356 2.7%  
Interest coverage x1.11.9 57.4%   
Debt to equity ratio x0.40.6 71.5%  
Sales to assets ratio x0.50.2 231.5%   
Return on assets %4.76.1 76.8%  
Return on equity %0.47.7 5.1%  
Return on capital %6.610.0 66.3%  
Exports to sales %017.2 0.0%   
Imports to sales %20.56.6 310.8%   
Exports (fob) Rs mNA11,362 0.0%   
Imports (cif) Rs m8584,364 19.7%   
Fx inflow Rs m014,435 0.0%   
Fx outflow Rs m8585,183 16.6%   
Net fx Rs m-8589,253 -9.3%   
CASH FLOW
From Operations Rs m469-67,773 -0.7%  
From Investments Rs m29-8,768 -0.3%  
From Financial Activity Rs m-46476,199 -0.6%  
Net Cashflow Rs m35-342 -10.1%  

Share Holding

Indian Promoters % 32.9 52.9 62.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 4.0 4.5%  
FIIs % 0.6 26.6 2.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 16.5 402.4%  
Shareholders   20,121 93,274 21.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Realty & Pharma Stocks Lead(09:30 am)

Asian stock indices are trading mixed today. The Shanghai Composite is lower by 0.29% while the Hang Seng is even. The Nikkei 225 is trading higher by 0.46%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 23, 2017 11:42 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS